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Abstract
Glucokinase (GK) acts as a glucose sensor in the pancreatic beta-cell and regulates insulin secretion. Heterozygous
mutations in the human GK-encoding GCK gene that reduce the activity index increase the glucose-stimulated insulin
secretion threshold and cause familial, mild fasting hyperglycaemia, also known as Maturity Onset Diabetes of the Young
type 2 (MODY2). Here we describe the biochemical characterization of five missense GK mutations: p.Ile130Thr, p.Asp205His,
p.Gly223Ser, p.His416Arg and p.Ala449Thr. The enzymatic analysis of the corresponding bacterially expressed GST-GK
mutant proteins show that all of them impair the kinetic characteristics of the enzyme. In keeping with their position within
the protein, mutations p.Ile130Thr, p.Asp205His, p.Gly223Ser, and p.His416Arg strongly decrease the activity index of GK,
affecting to one or more kinetic parameters. In contrast, the p.Ala449Thr mutation, which is located in the allosteric
activator site, does not affect significantly the activity index of GK, but dramatically modifies the main kinetic parameters
responsible for the function of this enzyme as a glucose sensor. The reduced Kcat of the mutant (3.2160.28 s21 vs
47.8662.78 s21) is balanced by an increased glucose affinity (S0.5 = 1.3360.08 mM vs 7.8660.09 mM) and loss of
cooperativity for this substrate. We further studied the mechanism by which this mutation impaired GK kinetics by
measuring the differential effects of several competitive inhibitors and one allosteric activator on the mutant protein. Our
results suggest that this mutation alters the equilibrium between the conformational states of glucokinase and highlights
the importance of the fine-tuning of GK and its role in glucose sensing.
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Introduction
Glucokinase (GK) plays a key role as the pancreatic beta-cell
glucose sensor by integrating blood glucose levels and glucose
metabolism with insulin secretion [1]. Besides the beta-cell, GK is
expressed in other neuroendocrine cells and in hepatocytes,
which participate in a network of cells involved in the body
glucose homeostasis [2]. This enzyme (also called hexokinase IV)
is one of the four hexokinase isoforms that catalyze the first
reaction of glycolysis converting glucose into glucose-6-phosphate
(G6P) with ATP as second substrate. The specific function of GK
as a glucose sensor is based on the particular regulatory
characteristics of this enzyme, as compared with the other
hexokinase isoforms, which are low affinity for glucose (S0.5 7–
9 mM, cooperativity with this substrate (Hill coefficient<1.7) and
lack of end-product inhibition at physiological concentrations of
G6P. In addition, and also in contrast to other hexokinase
isoforms, glucokinase activity might be modified by protein
interaction partners that can modulate the catalytic activity and
the intracellular distribution of the enzyme in beta-cells and/or
hepatocytes (for review see [3] [4] [5]. Yet, the best known
regulator of GK in the liver is the glucokinase regulatory protein
(GKRP) that acts as a competitive inhibitor with respect to
glucose and regulates the nucleo-cytoplasmic localization of the
enzyme to stabilize a protein reservoir of the enzyme in the
nucleus when its activity is not necessary [6] [7] [8].
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The crucial role of GK on beta-cell function is illustrated by the
fact that over 600 mutations in the GCK gene cause different
monogenic glycaemic disorders (for review see [9]). Thus,
heterozygous activating mutations cause persistent hyperinsulin-
emic hypoglycaemia of infancy (HI). In contrast, homozygous
inactivating mutations cause complete GK deficiency and
permanent neonatal diabetes mellitus (PNDM), whereas hetero-
zygous inactivating mutations cause familial, mild fasting hyper-
glycaemia also known as maturity-onset diabetes of the young type
2 (MODY2; [10] [11]). MODY2 patients show mild fasting
hyperglycaemia (5.5–8.0 mM) present from birth but usually are
asymptomatic and most remain undiagnosed until later in life [12].
These patients show little deterioration with age and usually do not
require any specific treatment [13]. The principal pathophysio-
logical mechanism of altered glycaemia in patients with GK
mutations is a beta-cell dysfunction characterized by a modifica-
tion in the blood glucose threshold that triggers insulin secretion,
which is consistent with a defect in glucose sensing [14] [15]. In
addition, abnormalities in liver glucose metabolism contribute to
the hyperglycaemia in patients with MODY2 [16]. Due to its
central role in controlling body glucose homeostasis, GK has been
considered as an outstanding drug target for developing new
antidiabetic therapies and several small molecular activators
(GKAs) have been discovered (for review see [5] [17]).
The determination of the human GK crystal structure defined
the active and allosteric activator sites and revealed the basis for
the catalytic mechanism of this enzyme thus allowing researchers
to analyze disease-associated mutations at the molecular level [18].
The functional characterization of naturally occurring GK
mutations has contributed to better knowledge of the biochemistry
of this enzyme. Activating mutations involved in HI increase
glucose affinity and most of them are clustered at the allosteric
activator site where GKAs bind [9] [18]. In contrast, hypergly-
caemia causing mutations are located throughout the protein and
most of them show a lower activity index, due to a reduction in
substrate affinity combined or not with decreased catalytic
turnover, which leads to an increased threshold for glucose-
stimulated insulin release [9] [19].
The present work reports the functional analysis of five missense
GK mutations: p.Ile130Thr, p.Asp205His, p.Gly223Ser, p.Hi-
s416Arg and p.Ala449Thr. The biochemical characterization of
these mutations shows that most of them are inactivating
mutations decreasing the activity index of the enzyme. Unexpect-
edly, the p.Ala449Thr mutation shows an overall activity index
that does not differ significantly from that of the wild type. In
contrast, it dramatically modifies the main kinetic parameters
responsible for the function of GK as a glucose sensor. By studying
the effect of one allosteric activator and some competitive
inhibitors on enzymatic activity, we analyzed the mechanisms by
which this mutation, located in the allosteric activator site, impairs
GK fine tuning.
Materials and Methods
Patients and mutation analysis of the GCK gene
The diabetic patients involved in this study were referred to our
laboratories for molecular testing of MODY2. The clinical
diagnosis was made using classical criteria [11]. All families were
of Spanish Caucasian descent with the exception of patient 4 who
was of Asian descent. Written informed consent was obtained from
the subjects or their parents. The studies were performed
according to the Declaration of Helsinki as revised in 2000 and
approved by the local Clinical Research Ethical Committees of the
two centres which conducted human genetic studies (Hospital
Clinico San Carlos/Universidad Complutense de Madrid and
Hospital Infantil Universitario Nin˜o Jesu´s, Madrid).
Mutation analysis of the GCK gene was performed as previously
described [20] [21].
Production of recombinant wild-type and mutant
glutathionyl-S-transferase-glucokinase (GST-GK) fusion
proteins
Recombinant human wild-type beta-cell glucokinase fused to
GST (GST-GK) was prepared as described previously [22].
MODY-associated mutations were introduced into the GST-GK
construct by PCR using the QuikChangeH II Site Directed
Mutagenesis Kit (Stratagene, La Jolla, Calif., USA). To generate
missense mutations p.Ile130Thr, p.Asp205His, p.Gly223Ser,
p.His416Arg and p.Ala449Thr the following oligonucleotides
were used, respectively: 59-ctacatctctgagtgcacctccgacttcctggac-39,
59-gatgtggtggccatggtgaatcacacggtggccacg-39, 59-gaggtcagcatgatcgt-
gggcacgggctgcaatgcatgctac-39, 59-ctccgtgtacaagctgcgcccaagcttcaa-
ggag-39, and 59-gaggagggcagcggccggggcacggccctgctg-39. Con-
structs carrying mutations p.Ile130Thr, p.Asp205His, p.Gly223-
Ser, p.His416Arg and p.Ala449Thr were checked by sequencing
and digestion with ApaLI, NcoI, NsiI, HindIII and Eco52I,
respectively. The expression and purification of fusion proteins
from E. coli was performed as described previously [22]. Fusion
proteins were stored at a concentration of about 1 mg/ml at
280uC in 30% glycerol, 50 mM glucose, 10 mM glutathione,
5 mM DTT, 200 mM KCl and 50 mM Tris/HCl pH=8.0.
Protein concentrations were determined using the Bio-Rad Protein
Assay (Bio-Rad Laboratories, GmbH), with bovine serum albumin
Table 1. Clinical characteristics of probands and GCK mutations.
Family
Age at diagnosis/
Current age (years)
Patient
sex
BMI
(kg/m2)
FPG
(mM)
OGTT
(mM)
HbA1c
(%)
Nucleotide
change
Protein
change
Affected family
members
1 3 yr3 mo/21 Female 15 6.1 5.8 5.8 c.389T.C p.Ile130Thre F, pGF
2 11 yr6 mo/19 Male 16.6 6.8 9.3 6.5 c.613G.C p.Asp205His M, S, mGF, mGM
3 13/19 Male 17 7.2 10.2 6.3 c.667G.A p.Gly223Ser F
4 1 yr11 mo/9 Female 17 6.3 11.1 5.7 c.1247A.G p.His416Arg Adopted
P99 27/31 Female 28 7.4 NA NA c.1345G.A p.Ala449Thr pGF, F
BMI: body mass index; FPG: fasting plasma glucose; OGTT: plasma glucose at 120 min after a standard oral glucose tolerance test (1.75 g per kg, ma´x. 75 g). Nucleotide
numbering uses +1 as the A of the ATG initiation codon, based on the GenBank sequence # NM_000162. F, father; M, mother; S, sister; pGF, paternal grandfather; mGF,
maternal grandfather; mGM, maternal grandmother. NA, not analysed. Underlined are those affected family members where mutation was checked by genotyping.
Novel mutations are shown in bold.
doi:10.1371/journal.pone.0030518.t001
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as standard. GST-GK purifications resulted in single bands of
75 kDa on Coomassie-stained SDS-PAGE.
Kinetic and structural analysis of the GK protein
Glucokinase activity was measured spectrophotometrically on a
spectrophotometer Uviconxl (Secoman), using an NADP+-coupled
assay with glucose-6-phosphate dehydrogenase, as described
previously [22]. The final reaction mixture contained 100 mM
Tris pH 7.4, 150 mM KCl, 1 mM MgCl2, 1.4 mM ß-mercapto-
ethanol, 0.1% BSA, 5 mM ATP-MgCl2, 1 mM NADP
+, and
1 U/ml glucose-6-phosphate dehydrogenase. Determination of
kinetic parameters and thermal stability tests were performed as in
[20]. Km for ATP was measured at a glucose concentration
corresponding to the S0.5 value for GST-GK wild-type and mutant
proteins (8, 9, 40, 70 and 3 mM, for wild-type, GST-GK(p.I-
le130Thr), GST-GK(p.Gly223His), GST-GK(p.His416Arg) and
GST-GK(p.Ala449Thr), respectively. The relative activity index
was calculated as previously [19]. Concentrations of inhibitors
causing 50% inhibition (I50) were derived from Dixon plots [23],
using different concentrations of glucose (2, 5 and 8 mM for the
wild-type protein, 12.5, 25 and 50 mM or 1, 1.5 and 2 mM for
proteins carrying mutations p.Gly223Ser and p.Ala449Thr,
respectively), and five concentrations of inhibitors (0.05, 0.1,
0.25, 0.5 and 1 mM for N-acetylglucosamine (NAG); 0.5, 1, 2, 5
and 10 mM for mannoheptulose (MH) and 1, 2, 5, 10 and 15 mM
for palmitoyl-CoA). Inhibition by NAG and MH was determined
under standard assay conditions with 50 nM glucokinase [22].
The inhibition by palmitoylCoA was determined in reaction
mixtures containing 25 mM Hepes pH 7.1; 25 mM KCl; 1 mM
NADP, 1 mM ATP-MgCl2; 2.5 mM MgCl2; 5 mM ß-mercapto-
ethanol, 1 U/ml glucose-6-phosphate dehydrogenase and 61 nM
glucokinase [24]. Due to the low Kcat value of mutant GST-
GK(pAla449Thr), the amount of protein used in inhibition assays
was 180 nM to get sufficient activity to allow for accurate
determination of the inhibitor effect. In these conditions, GK
activity (U/mg of GST-GK(pAla449Thr)) in the absence of
inhibitors was 1.360.08, 1.160.06 and 0.960.05 at 2, 1.5 and
1 mM of glucose, respectively for NAG and MH assays and
Table 2. Kinetic constants of human recombinant wild type and MODY2 mutant beta-cell GST-GK fusion proteins.
Preparation
Protein yield
(mg/l) Kcat (s21)
S0.5 for glucose
(mM) nH Km for ATP (mM) Ia
Wild-type GST-GK
(n= 7)
4.8360.02 47.8662.78 7.8660.09 1.4960.02 0.5460.01 1.060.09
GST-GK (p.Ile130Thr)
(n= 4)
14.360.14 2.8860.29* 8.5960.45 1.0160.02* 0.1360.02** 0.1760.03*
GST-GK (p.Asp205His)
(n= 2)
7.7/3.3 No activity at all
GST-GK (p.Gly223Ser)
(n= 5)
7.7560.07 12.9060.52* 44.063.81* 1.1360.01* 1.6060.1* 0.06460.010*
GST-GK (p.His416Arg)
(n= 4)
6.5560.003 1.0260.08* 67.962.27* 1.0060.02* 3.7460.10* 0.00360.0004*
GST-GK (p.Ala449Thr)
(n= 6)
9.6560.065 3.2160.28* 1.3360.08* 0.9560.02* 1.8160.08* 1.2360.16
Data represent means 6 SEM of n separate experiments from at least two independent enzyme purifications. The Hill coefficient (nH) and the relative activity index (Ia)
are unit less. (*) p,0.0007; (**) p= 0.012.
doi:10.1371/journal.pone.0030518.t002
Figure 1. Effect of temperature on the stability of the GST-GK(p.Ala449Thr) protein. Stock enzyme solutions were diluted to 250 mg/ml in
buffer containing 30% glycerol, 50 mM glucose, 10 mM glutathione, 5 mM dithiothreitol, 200 mM KCl and 50 mM Tris/HCl, pH 8.0. A) The enzyme
solutions were incubated for 30 min at different temperatures ranging from 30 to 55uC and then assayed at 30uC as described in Material and
Methods. B) The enzyme solutions were incubated for different periods of time from 5 to 60 min at 50uC. Means and SEM of three independent
enzyme preparations are shown.
doi:10.1371/journal.pone.0030518.g001
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0.560.05, 0.3360.03 and 0.2760.03 at 2, 1.5 and 1 mM glucose,
respectively for palmitoyl-CoA assay.
Purified human GKRP was kindly provided by KJ Brocklehurst
(Cardiovascular and Gastrointestinal Department, AstraZeneca,
Macclesfield, Cheshire SK10 4TG, UK). The effect of GKRP on
glucokinase activity was determined as described [25]. The final
reaction mixture contained 25 mM Hepes pH 7.1; 25 mM KCl;
1 mM NADP, 1 mM ATP-MgCl2; 2.5 mM MgCl2; 5 mM ß-
mercaptoethanol, 1 U/ml glucose-6-phosphate dehydrogenase,
61 nM of GST-GK or 180 nM GST-GK(pAla449Thr), 5 mM
glucose, GKRP (0 to 200 nM) and, when indicated, 10 mM
sorbitol-6-phosphate (S6P) or 0.2 mM fructose-1-phosphate (F1P).
In these conditions, GST-GK(pAla449Thr) activity in the absence
of GKRP was 0.860.09 U/mg of protein.
One unit of GK is defined as the amount of enzyme that
phosphorylates 1 mmol of glucose per min at 30uC.
GK activator LY2121260 was kindly provided by Elli Lilly and
Co, Indianapolis, IN, USA. A stock solution of 1 mM LY2121260
was prepared in 12.5 mM Hepes pH 7.4 with 80% DMSO. Results
are shown as means6 SEM, and statistical significance was analysed
by the two-tailed Student’s t-test. P values of ,0.05 were considered
statistically significant. The structural analysis of mutations was
carried out using the crystal structure of human GK [18] and
visualized using the PymolMolecular Graphics System (Schro¨dinger).
Two-hybrid analysis
Two-hybrid studies were performed in S. cerevisiae strain Y187 as
described previously [20]. Plasmids encoding a GKRP fusion
Figure 2. Effect of mutation p.Ala449Thr on the GK interaction with GKRP. A) Inhibition of glucokinase activity by human GKRP. Enzyme
activity was measured at 5 mM glucose as described in Material and Methods, in the presence of 10 mM S6P (left panel) or 0.2 mM F1P (right panel).
Results are means 6 SEM for three independent enzyme purifications assayed in triplicate. B) Two-hybrid interaction of GBD-GKRP with GAD-GK or
GAD-GK(p.Ala449Thr) mutant. Yeast strain Y187 was used, and fusion proteins were expressed from pGBKT7 and pACTII derivatives. Values are means
6 SEM from ß-galactosidase activity of six independent transformants. In control experiments, GBD-GKRP did not interact with GAD and GAD-GK did
not interact with GBD [22].
doi:10.1371/journal.pone.0030518.g002
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protein to the Gal4 Binding Domain (GBD) in the pGBKT7
vector (Clontech) and a fusion of GK to the Gal4 Activating
Domain (GAD) in the pACTII (Clontech), have been described
previously [22]. Plasmid encoding the GK(p.Ala449Thr) mutant
derivative was derived from pACTII by inserting a BamHI-XhoI
fragment from the GST-GK(p.Ala449Thr) construct containing
the mutant GK coding sequence between the same sites of the
polylinker.
Results
Clinical features of probands and mutations in the GCK
gene
Table 1 shows the clinical presentation of probands in the 5
families, consistent with a clinical diagnosis of MODY2 in all
cases. All of these patients were treated with diet alone. A GCK
heterozygous missense mutation was identified in each family.
Three mutations (p.Ile130Thr, p.Gly223Ser, and p.Ala449Thr)
had been previously reported as a cause of MODY [9] [26]. Two
mutations were novel (p.Asp205His, p.His416Arg). Proband 2
inherited the p.Asp205His mutation from his affected mother; it
was also found in an affected sister but not in his unaffected father.
Proband 4 had been adopted from China and DNA from her
biological relatives was not available for testing.
Biochemical analysis of recombinant mutant
glucokinases
Recombinant wild-type GST-GK and mutants GST-GK(p.I-
le130Thr), GST-GK(p.Asp205His), GST-GK(p.Gly223Ser),
GST-GK(p.His416Arg) and GST-GK(p.Ala449Thr) were pre-
pared in E. coli. Kinetic parameters of purified fusion proteins are
shown in Table 2. Mutation p.Asp205His produced the strongest
effect on GK, since this mutant enzyme showed no measurable
activity despite the good protein yield obtained after purification.
Mutants GST-GK(p.Ile130Thr), GST-GK(p.Gly223Ser) and
GST-GK(p.His416Arg) showed an overall activity lower than
20, 10 and 0.5% of the wild-type protein respectively, which is
reflected in the relative activity index (Ia) values. Among these
mutations p.Gly223Ser and p.His416Arg significantly affected all
the kinetic parameters. Both mutations decreased the affinity of
GK for both substrates glucose and ATP, and also decreased the
catalytic constant (Kcat) and the Hill coefficient (nH) of the
enzyme. In contrast, mutation p.Ile130Thr, which also decreased
the Kcat and the nH, increased the affinity of GK for ATP
without modifying the affinity for glucose.
Mutant GST-GK(p.Ala449Thr) had an in vitro activity index
slightly higher than the wild-type protein, although this difference
was not statistically significant (p=0.11). However, and despite this
apparent normal activity level, this mutation affects all the kinetic
parameters of GK individually. The mutant protein GST-
GK(p.Ala449Thr) lacked the cooperativity for glucose, as shown
by a significantly decreased Hill coefficient. The Kcat of this
mutant was reduced to 7% of the wild-type value and the affinity
for ATP was decreased more than 3-fold. In contrast, and
unusually for MODY2 mutations, affinity for glucose was strongly
increased in about 5-fold. The protein stability of mutant GST-
GK(p.Ala449Thr) was tested at different temperatures and
compared to that of the wild-type fusion protein. Figure 1A shows
that the activity of both wild type and mutant GST-GK(p.A-
la449Thr) was not significantly altered after 30 minutes of
incubation up to 52uC but drastically fell at 55uC. Additionally,
no significant differences in the relative activity were observed
between both proteins when incubated up to 60 min at the
constant temperature of 50uC (Figure 1B). These results indicate
that mutation p.Ala449Thr did not confer thermal instability.
To further investigate the mechanism by which mutation
p.Ala449Thr increased the affinity of GK for glucose, we tested
the effects on both mutant and wild-type enzymes, of some
competitive GK inhibitors such as N-acetylglucosamine (NAG),
mannoheptulose (MH), palmitoyl-CoA, as well as the glucokinase
regulatory protein (GKRP). Palmitoyl-CoA and GKRP bind to
distinct allosteric sites, whereas glucose analogues NAG and MH
bind to the catalytic site of the open and closed conformations,
respectively [27]. It has been described that mutations of residues
in the catalytic site affect the affinities for glucose, MH and NAG,
whilst mutations of residues distant form the catalytic site affect the
affinity for glucose and MH but not for NAG [28], [29], [27]. In
addition, it has been previously proposed that differences in
GKRP binding affinity between GK mutants reflect the
mechanism by which mutations increase the glucose binding
affinity [30]. As shown in Figure 2A, enzymatic inhibition by
GKRP in the presence of either S6P or F1P was the same for the
wild type and GST-GK(p.Ala449Thr) mutant. Lack of effect of
this mutation on the GK-GKRP protein-protein interaction was
corroborated by the two-hybrid system in yeast (Figure 2B). The
sensitivity of GK to NAG, MH and palmitoyl-CoA was measured
for both GST-GK(p.Ala449Thr) and GST-GK(p.Gly223Ser)
mutant proteins, the latter showing a strongly decreased glucose
affinity but still measurable enzymatic activity. The inhibition
profiles for GST-GK activity are shown in Figure 3. Table 3 shows
that the sensitivity of GK to these inhibitors, which is reflected by
the I50 value, is significantly affected for the GK(p.Gly223Ser)
mutant with respect to the wild-type enzyme. In contrast,
mutation p.Ala449Thr did not affect the inhibition by NAG but
decreased the I50 for MH and palmitoyl-CoA by about 35 and
26%, respectively.
Finally, we studied the effects of the GK synthetic allosteric
activator LY2121260 on the kinetic parameters of GST-GK(p.A-
Figure 3. Inhibition of GK activity by mannoheptulose (MH), N-
acetylglucosamine (NAG) and palmitoyl-CoA. The GST-GK en-
zyme was assayed at 5 mM glucose with the indicated concentration of
inhibitors as described in Material and Methods. Means and SEM of
three independent enzyme preparations are shown.
doi:10.1371/journal.pone.0030518.g003
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la449Thr) and compared them to those on the GST-GK wild-type
protein (Table 4). For the wild-type fusion protein, the Kcat was
increased by about 30% and the affinity for glucose was about 5
fold higher in the presence of 10 mM of this activator. In contrast,
LY2121260 did not affect GST-GK(p.Ala449Thr) S0.5 but
produced a slight recovery of Kcat up to about 20% of the
normal wild-type value.
Discussion
In this report we describe the functional analysis of five GCK
mutations identified in probands with familial, mild fasting
hyperglycaemia. The biochemical characterization of these
mutations has shown that all of them impair normal glucokinase
activity. The molecular analysis of these mutations revealed the
particular defects caused in GK enzymatic activity.
The structural data obtained from the free and substrate/
activator bound GK crystals showed that this enzyme has a small
and a large domain separated by a deep cleft where substrates bind
[18]. Glucokinase may adopt three structural conformations. In
the absence of glucose, GK is in an inactive super-open
conformation. Following glucose binding, the enzyme undergoes
a conformational change leading to, first, an intermediate open
conformation and then, a fully active closed conformation, which
binds ATP. The transition between the super-open and closed
conformations involves the rotation and approximation of the
small domain to the large one. The existence of GK in different
conformations allows two catalytic cycles, fast and slow, that
explain the sigmoidal response to glucose [18]. Asp205, His416
and Gly223 are highly conserved amino acids among glucokinases
and hexokinases and, in agreement with their localization within
or in close proximity to the catalytic site (Figure 4), are essential for
GK activity as shown by the strongest overall activity defects
produced by mutations p.Asp205His, p.His416Arg and p.Gly223-
Ser. Our results show that the novel mutation p.Asp205His
abolishes GK enzymatic activity. This result was predictable since
the interaction between Asp205 and glucose is necessary to trigger
the conformational change between the inactive and active
conformations of GK [18]. Mutations p.His416Arg and p.Gly223-
Ser severely inactivated the enzyme by impairment of all kinetic
parameters. Gly223 and His416 do not interact directly with
glucose or ATP, but they are part of the active site of GK along
with other neighbouring residues [31] [18] [32] [33]. His416 is
located in the a11’ helix in the large domain (Figure 4A). The
larger size of the side chain of the arginine residue in the
p.His416Arg mutation would be projected into surrounding a
helices and could force a structural reorganization of that region of
the protein (Figure 4B). Gly223 is localized in the ß9 strand, in the
large domain (Figure 4A and 4C). The change of a small residue,
glycine, to serine could also produce steric impediments with
surrounding residues Thr206 and Met210 in the a5 helix, which
are inside the active site and were previously found to be
important for GK activity [19] [34] [35] [22]. In contrast to
Asp205, His416 and Gly223, Ile130 is located in a peripheral
position far from the catalytic site, in the a3 helix within the small
domain (Figure 4A). This residue is projected into the hydrophobic
core of the small domain. Mutation p.Ile130Thr introduces a
polar residue in this hydrophobic region, which might alter the
stability of the core and the structure and dynamics of the domain
(Figure 4D). Accordingly, our biochemical analyses have shown
that the decrease in Kcat is the main deleterious defect caused by
mutation p.Ile130Thr on GK activity. Although affinity for
glucose is not altered by this mutation, the affinity for the second
substrate, ATP is increased. This latter effect was also observed for
the MODY2 mutation p.Ser131Pro [36], suggesting a role of this
region of the protein in the regulation of the affinity for this
substrate.
The activity index obtained from the kinetic analyses of these
mutants might be sufficient to explain the pathogenic effect of
mutations p.Asp205His, p.His416Arg, p.Gly223Ser and
p.Ile130Thr, since there is a direct relationship between this
parameter and the glucose-stimulated insulin secretion threshold
in a heterozygous mutant [19] [34]. However, this rule does not
apply for mutation p.Ala449Thr since the corresponding activity
index does not differ significantly from that of the wild type
enzyme. This mutation did not confer thermal instability,
suggesting that it does not affect the stability of the protein. In
addition, possible defects in the regulation of this mutant by
GKRP in the liver are unlikely since this mutation has no effect on
the interaction of GK with GKRP. In contrast, the main kinetic
characteristics of glucokinase, which play a key role in the function
of this enzyme as a glucose sensor, ie low affinity for glucose and
cooperativity, are lost in this mutant protein.
Table 4. Effect of GK synthetic activator LY2121260 on wild
type and mutant GST-GK fusion proteins.
Preparation Kcat (%) S0.5 for glucose (mM)
Buffer LY2121260 Buffer LY2121260
Wild-type GST-GK 10065.3 130.863.9** 7.9060.3 1.760,1**
GST-GK(p.Ala449Thr) 13.960.8 19.461.5* 2.760.3 3.160.3
GK activity was measured in standard conditions, as described in Material and
Methods, in the absence and presence of 10 mM GK activator. Since LY2121260
was dissolved in a buffer containing DMSO, all assays contained a final
concentration of 0.8% DMSO. Data represent means 6 SEM of at least four
separate experiments from two independent enzyme purifications. Statistical
significance has been estimated comparing values in the presence of
LY2121260 versus their corresponding values in the presence of buffer.
(**) p,0.005; (*) p= 0.023.
doi:10.1371/journal.pone.0030518.t004
Table 3. Effect of MODY2 mutations p.Gly223Ser and p.Ala449Thr on the affinity of GK for N-acetylglucosamine (NAG),
mannoheptulose (MH) and palmitoyl-CoA.
Preparation I50 for NAG (mM) I50 for MH (mM) I50 for palmitoyl-CoA (mM)
Wild-type GST-GK 0.2160.04 1.1560.37 3.0660.27
GST-GK(pGly223Ser) 0.3860.045** 3.5560.63** 1.4260.13**
GST-GK(p.Ala449Thr) 0.2060.06 0.6760.04** 2.2460.14*
Concentrations of inhibitors causing 50% inhibition (I50) were derived from Dixon plots as described in Materials and Methods. Data represent means 6 SEM of at least
four separate experiments from at least two independent enzyme purifications. (**) p,0.006. (*) p=0.03.
doi:10.1371/journal.pone.0030518.t003
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Ala449 is located in the a13 helix which is the C-terminal
region of glucokinase (Figure 4A). The a13 helix forms part of the
allosteric activator site and plays a key role in the conformational
change between the active and inactive forms of glucokinase [18]
[37] [38]. In contrast to other hyperglycaemia-associated GK
mutations in a13 helix, mutation p.Ala449Thr did not appear to
affect global GK activity. The increase in the Km value for ATP
may not be relevant since it still remains below the intracellular
ATP concentration [19]. The reduced Kcat is compensated by an
increased glucose affinity and loss of cooperativity for this
substrate, resulting in a catalytic efficiency (Kcat/S0.5
h) similar to
that of the wild-type (2.4460.39 vs 2.2960.23). In the structural
model of GK, the side chain of alanine or threonine at position
449 is projected to the solvent in the super-open inactive
conformation (Figure 4F). In contrast, these residues are facing
the b sheet of the small domain in the closed conformation
Figure 4. Localization of mutations in the structural model for beta-cell glucokinase. A) Localization of mutated residues in the closed
conformation of GK. A to E) An enlargement of the region of interest is shown in each panel. F) Representation of mutation p.Ala449Thr in the super-
open conformation of GK. Wild type residues are in black, whereas the mutated residues are magenta. Surrounding disturbing structures are in blue.
Glucose is represented in green whereas activator compound A is in yellow. The closed (1V4S) and the super-open (1V4T) conformations of GK [18]
are represented using the Pymol Molecular Graphics System (Schro¨dinger).
doi:10.1371/journal.pone.0030518.g004
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(Figure 4E). The larger and polar side chain of threonine at
position 449 may alter the equilibrium between the conforma-
tional states of glucokinase. The high affinity for glucose exhibited
by GST-GK(p.Ala449Thr) suggests that the closed conformation
is stabilized in this mutant. This hypothesis is supported by an
increase in affinity for GK inhibitor MH which binds to the
catalytic site in the closed conformation of the enzyme [27].
Palmitoyl-CoA and GKRP appear to bind to distinct allosteric
sites of the enzyme that could overlap in the hinge region and
would act by interfering with the closure of the catalytic cleft [39]
[29] [27]. Our results indicate that mutation p.Ala449Thr does
not alter the interaction of GK with GKRP. However, the
sensitivity to palmitoyl-CoA was increased in mutant proteins
GST-GK(p.Gly223Ser) and GST-GK(p.Ala449Thr), suggesting
that these mutations have some effect on the putative binding site
for acyl-CoA esters in the large domain of the enzyme [29]. It has
been proposed that GK activators avoid the super-open form and
stabilize the open one to increase affinity for glucose and Vmax,
respectively [18]. The compound LY2121260 binds to the
allosteric activator site of the enzyme and activates the enzyme
in a similar fashion [38]. The fact that mutation p.Ala449Thr
decreases Kcat and S0.5 to a similar extent suggests non-productive
substrate binding or blockage in substrate release, which could be
due to an impairment of this mutant protein to return to its open
form in order to release G6P and ADP [18]. Consistently, our
results show that the compound LY2121260 had no further effect
on GST-GK(p.Ala449Thr) affinity for glucose and slightly relieved
the defect on catalytic constant.
In summary, the results of the biochemical analysis of these
different MODY2-causing mutations illustrate the importance of
the fine tuning of GK and its role in glucose sensing, and provide
further insights into the role of the catalytic and allosteric activator
sites in the regulation of the activity of this enzyme.
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